News

Bayer adds cancer drug candidate to portfolio

Bayer, Kumquat Biosciences Team Up on New Potential Cancer Drug
Under the global exclusive license deal, Kumquat will be responsible for the Phase 1a study of its inhibitor and Bayer will take the drug to market.
Bayer, Kumquat Biosciences Partner to Develop & Commercialize KRAS G12D Inhibitor
Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor.
Bayer adds cancer drug candidate to portfolio with $1.3-billion Kumquat deal
BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.
Bayer buys into KRAS with $1.3bn Kumquat deal
The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive global rights to a KRAS G12D inhibitor developed by San Diego-based Kumquat that is on the brink of starting human trials in the US.
Bayer Makes Potential $1.3B Cancer Bet in Kumquat Deal
For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat Biosciences’ small-molecule KRAS G12D blocker.
Retail Turns Bearish On Bayer After $1.3B Kumquat Cancer Drug Deal
Bayer and Kumquat Biosciences have signed an exclusive global license and collaboration to develop a KRAS G12D inhibitor, with potential milestone payments of up to $1.3 billion
Bayer inks $1.3 billion deal with Kumquat Biosciences for cancer drug development
Bayer (BAYZF) on Tuesday unveiled a partnership deal worth up to $1.3 billion with Kumquat Biosciences to develop the U.S.-based oncology specialist's potential new cancer drug.
Fierce Biotech1d

Bayer picks Kumquat for KRAS collaboration, with $1.3B on offer if pact bears fruit

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...
PharmExec1d

Bayer Agrees to Exclusive License and Collaboration Effort with Kumquat Biosciences for Development of Kras G12D Inhibitor

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...
PharmiWeb1d

Bayer teams up with Kumquat to develop KRAS G12D oncology candidate

Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...
Pharmabiz1d

Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor

Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor: Berlin, Germany Wednesday, August 13, 2025, 11:00 ...